Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies

Research output: Contribution to journalComment/debatepeer-review

Abstract

In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al.1 compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.

Original languageEnglish (US)
Pages (from-to)487-489
Number of pages3
JournalMed
Volume5
Issue number6
DOIs
StatePublished - Jun 14 2024

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies'. Together they form a unique fingerprint.

Cite this